334970 — Prestige Biologics Cashflow Statement

0.000.00%

Last trade - 00:00

HealthcareSpeculativeSmall CapSucker Stock

Annual cashflow statement for Prestige Biologics, fiscal year end - June 30th, KRW millions except per share, conversion factor applied.

	2022 December 31st	2023 June 30th	2024 June 30th	2025 June 30th	2026 June 30th
Period Length:	12 M	6 M	12 M	12 M	12 M
Source:	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts
Standards:	IFRS	IFRS	IFRS	IFRS	IFRS
Status:	Final	Final	Final	Final	Final
Net Income/Starting Line	-49,718	-17,980	-29,374	-27,469	-51,220
Depreciation
Amortisation
Non-Cash Items	19,835	11,157	-9,771	-2,764	11,279
Unusual Items
Purchased R&D
Other Non-Cash Items
Changes in Working Capital	-12,245	-1,870	19,569	-1,176	31,372
Change in Accounts Receivable
Change in Inventories
Change in Prepaid Expenses
Change in Accounts Payable
Change in Accrued Expenses
Change in Other Liabilities
Other Operating Cash Flow
Cash from Operating Activities	-34,190	-4,450	-8,345	-18,327	3,203
Capital Expenditures	-84,790	-19,495	-8,637	-5,656	-3,139
Purchase of Fixed Assets
Purchase / Acquisition of Intangibles
Other Investing Cash Flow Items	1,124	18.2	711	97.7	129
Sale of Fixed Assets
Sale of Intangible Assets
Other Investing Cash Flow
Cash from Investing Activities	-83,665	-19,477	-7,927	-5,558	-3,010
Financing Cash Flow Items	-42.7	—	-52.3	-51.2	—
Other Financing Cash Flow
Net Issuance / Retirement of Stock
Net Issuance / Retirement of Debt
Cash from Financing Activities	96,463	53,979	345	-4,041	5,136
Beginning Cash Balance
Ending Cash Balance
Net Change in Cash	-21,392	30,052	-15,928	-27,926	5,361